What is claimed is:

1. Use of an interleukin-4 receptor (IL-4R) antagonist for the manufacture of a medicament for treating moderate-to-severe atopic dermatitis (AD), wherein the IL-4R antagonist is an antibody or an antigen-binding fragment thereof that binds IL-4R, wherein the antibody or antigen-binding fragment thereof comprises three HCDRs (HCDR1, HCDR2 and HCDR3) and three LCDRs (LCDR1, LCDR2 and LCDR3), wherein the HCDR1 comprises the amino acid sequence of SEQ ID NO:148, the HCDR2 comprises the amino acid sequence of SEQ ID NO:150, the HCDR3 comprises the amino acid sequence of SEQ ID NO:152, the LCDR1 comprises the amino acid sequence of SEQ ID NO:156, the LCDR2 comprises the amino acid sequence of SEQ ID NO:158, and the LCDR3 comprises the amino acid sequence of SEQ ID NO:160;

wherein the medicament is administered to a patient having moderate-to-severe AD at an initial dose of the IL-4R antagonist followed by at least eight secondary doses of the IL-4R antagonist.

2. The use of claim 1, wherein each dose comprises about 50 mg to about 600 mg of the IL-4R antagonist.

3. The use of any one of claims 1 to 2, wherein:
(a) the initial dose comprises 600 mg of the IL-4R antagonist and each secondary dose comprises 300 mg of the IL-4R antagonist; or
(b) the initial dose comprises 400 mg of the IL-4R antagonist and each secondary dose comprises 200 mg of the IL-4R antagonist.

4. The use of any one of claims 1 to 3, wherein each secondary dose is administered to the patient 1 to 2 weeks after the immediately preceding dose.

5. The use of claim 4, wherein:
(a) the initial dose comprises 600 mg of the IL-4R antagonist and secondary dose comprises 300 mg of the IL-4R antagonist, wherein each secondary dose is administered 2 weeks after the immediately preceding dose; or
(b) the initial dose comprises 400 mg of the IL-4R antagonist and secondary dose comprises 200 mg of the IL-4R antagonist, wherein each secondary dose is administered 2 weeks after the immediately preceding dose.

6. The use of any one of claims 1 to 5, wherein the antibody or antigen-binding

fragment comprises a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 162 and a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 164.

7. The use of any one of claims 1 to 6, wherein the IL-4R antagonist is administered to the patient subcutaneously.

8. The use of any one of claims 1 to 7, wherein the patient is an adult.

9. The use of any one of claims 1 to 7, wherein the patient is an adolescent.

10. The use of any one of claims 1 to 9, wherein the use further comprises administering to the patient a second therapeutic agent.

11. The use of claim 10, wherein the second therapeutic agent:
(a) is selected from the group consisting of a TNF inhibitor, an IL-1 inhibitor, an IL-5 inhibitor, an IL-8 inhibitor, an IgE inhibitor, a NSAID, and IFNγ; or
(b) is a topical corticosteroid (TCS) or a topical calcineurin inhibitor.

12. The use of any one of claims 1 to 11, wherein the IL-4R antagonist is contained in a container selected from the group consisting of a syringe, a pre-filled pen delivery device, an autoinjector, a glass vial, and a microinfusor.